FDA warns Dallas eye practice Cornea Associates for running a 69-subject drug study without an IND.
What happened
FDA inspected Cornea Associates of Texas, in Dallas, from September 12 to 19, 2022, reviewing its role as sponsor of two clinical investigations and Dr. McCall's role as sponsor representative and clinical investigator. FDA found the practice started and ran a study of a combination product of investigational drugs in 69 human subjects without submitting or having in effect an Investigational New Drug application (IND, the FDA permission needed before testing an unapproved drug in people).
What FDA found
The sponsor began and ran a study of an unapproved drug combination in 69 people without first submitting and holding an IND.
21 CFR 312.20(a), 312.20(b), 312.40(a)The product was not lawfully marketed in the United States, so the study did not qualify for an IND exemption.
21 CFR 312.2The sponsor, not the IRB, is responsible for complying with IND rules.
21 CFR part 312The company's written response was inadequate because it did not explain how it will decide when an IND is needed, how it will hold the planned pre-IND meeting, or what training staff will get.
What FDA wants
Within 15 business days of receiving the letter, notify FDA in writing of the actions taken to prevent similar violations, or provide reasoning and supporting information if the company believes it complied.
Who should pay attention
- physician practices acting as sponsors of their own studies
- IRBs and research staff reviewing IND requirements
- small sponsors running investigator-initiated drug trials
This is a summary. Read the original letter on fda.gov.